Wells Fargo Maintains Overweight on Relay Therapeutics, Raises Price Target to $17

Wells Fargo analyst Eva Fortea Verdejo has maintained an Overweight rating on Relay Therapeutics (NASDAQ: RLAY) and increased the price target from $15 to $17. This adjustment reflects a positive outlook for the company's stock performance.